SCHEMBL2843751

SCHEMBL2843751

Cc1ccc(S(=O)(=O)Nc2ccc(C(C(=O)NO)c3ccccc3)cc2)cc1C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 2/20 0.57
MAPT P10636 2/20 0.56
HTT P42858 1/20 0.56
RECQL P46063 1/20 0.56
PKM P14618 3/20 0.50
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
HDAC1 Q13547 2/20 0.50
PKLR P30613 1/20 0.50
HDAC3 O15379 1/20 0.50
HDAC7 Q8WUI4 1/20 0.50
HDAC2 Q92769 1/20 0.50
HDAC10 Q969S8 1/20 0.50
HDAC11 Q96DB2 1/20 0.50
HDAC8 Q9BY41 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
HDAC9 Q9UKV0 1/20 0.50
HDAC5 Q9UQL6 1/20 0.50
IDH2 P48735 1/20 0.48
ALDH1A1 P00352 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20490570 0.91 MAPT (0.54) HDAC4MAPTHTTRECQLPKM
SCHEMBL2841161 0.90 PKM (0.54) HDAC4MAPTHTTRECQLPKM
SCHEMBL2837267 0.86 HDAC4 (0.63) HDAC4MAPTMEN1KMT2AHDAC1
SCHEMBL20490193 0.86 HDAC4 (0.60) HDAC4MAPTMEN1KMT2AHDAC1
SCHEMBL2844146 0.85 HDAC4 (0.59) HDAC4MAPTHTTRECQLMEN1
SCHEMBL2844092 0.85 HDAC4 (0.74) HDAC4PKMMEN1KMT2AHDAC1
SCHEMBL2846670 0.84 HDAC1 (0.59) HDAC4MAPTPKMMEN1KMT2A
SCHEMBL2869450 0.83 CA12 (0.65) HDAC4HTTPKMMEN1KMT2A
SCHEMBL2841116 0.82 ALDH1A1 (0.57) HDAC4MAPTPKMMEN1KMT2A
SCHEMBL20490290 0.82 KMT2A (0.64) HDAC4MEN1KMT2AHDAC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2139850-B1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC (CA) 2018-09-12 EP claimed
EP-2139850-A1 INHIBITORS OF HISTONE DEACETYLASE Methylgene, Inc. (CA) 2010-01-06 EP claimed
US-20090181943-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2009-07-16 US claimed
WO-2008122115-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2008-10-16 WO claimed
EP-2139850-B1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC (CA) 2018-09-12 EP disclosed
US-9096565-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2015-08-04 US disclosed
EP-2139850-A1 INHIBITORS OF HISTONE DEACETYLASE Methylgene, Inc. (CA) 2010-01-06 EP disclosed
US-20090181943-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2009-07-16 US disclosed
WO-2008122115-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2008-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181943-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC11, HDAC3 HDAC4 10/4885MAPT 1533/4885HTT 1010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.